Introduction {#sec1}
============

Viral hepatitis refers to a group of infectious disorders caused by various kinds of hepatitis viruses (hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV) and hepatitis E virus (HEV)), and it could lead to life-threatening conditions including cirrhosis, liver failure or hepatocellular carcinoma \[[@ref1], [@ref2]\]. Although the exact mechanism of its pathogenesis is still uncertain, it was believed that genetic architecture was essential for the development of viral hepatitis. In the first place, the incidences of viral hepatitis in different populations vary greatly \[[@ref3], [@ref4]\], and genetic background was probably one of the reasons behind differences in disease prevalence across different populations. In the second place, previous association studies also identified numerous susceptible genetic loci of viral hepatitis \[[@ref5], [@ref6]\]. However, genetic factors that contribute to the development of viral hepatitis are still not fully elucidated.

Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and interleukin-18 (IL-18) are pro-inflammatory cytokines, and they both serve as crucial modulators of anti-viral immune responses \[[@ref7], [@ref8]\]. Therefore, if a genetic polymorphism could alter the transcription activity of *CTLA-4*/*IL-18* or the protein structure of *CTLA-4/IL-18*, it is biologically plausible that this polymorphism may also impact anti-viral immune responses and confer susceptibility to many types of infectious diseases including viral hepatitis.

In the past 20 years, results about associations between polymorphisms in *CTLA-4/IL-18* and viral hepatitis were already reported by many association studies, yet the conclusions of these studies were still inconsistent. To better analyse associations between polymorphisms in *CTLA-4/IL-18* and viral hepatitis, we carried out this study to get a more statistically reliable conclusion by combing the results of all relevant studies.

Materials and methods {#sec2}
=====================

This meta-analysis was written in accordance with the PRISMA guideline \[[@ref9]\].

Literature search and inclusion criteria {#sec2-1}
----------------------------------------

To retrieve eligible articles, we searched Pubmed, Web of Science and Embase using key words listed below: ('interleukin-18' or 'IL-18' or 'interleukin 18' or 'IL 18' or 'cytotoxic T lymphocyte antigen-4' or 'CTLA-4') and ('polymorphism' or 'variant' or 'variation' or 'mutation' or 'SNP' or 'genome-wide association study' or 'genetic association study' or 'genotype' or 'allele') and ('viral hepatitis' or 'chronic hepatitis' or 'acute hepatitis' or 'Hepatitis A' or 'Hepatitis B' or 'Hepatitis C' or 'Hepatitis D' or 'Hepatitis E' or 'HAV' or 'HBV' or 'HCV' or 'HDV' or 'HEV'). The references of retrieved articles were also screened by us in case some related articles may be missed by our electronic literature searching.

To be included in this meta-analysis, some criteria must be satisfied: (I) studies about associations between polymorphisms in *CTLA-4*/*IL-18* and viral hepatitis in humans; (II) offer genotypic or allelic distribution of *CTLA-4/IL-18* polymorphisms in patients with viral hepatitis and controls and (III) full manuscript in English or Chinese is retrievable. We only included the most up-to-date study if duplicate reports were found during literature search.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

Two authors extracted following information from eligible articles: (I) name of the first author; (II) published year; (III) country where the study was conducted; (IV) ethnicity of involved participants; (V) number of patients with viral hepatitis and controls in each study and (VI) genotype distributions of polymorphisms in *CTLA-4/IL-18* among patients with viral hepatitis and controls. *P* Values of Hardy--Weinberg equilibrium (HWE) were also calculated.

The authors used Newcastle--Ottawa scale (NOS) to assess the methodology quality of eligible articles \[[@ref10]\]. The score range of NOS is between zero and nine, when an article got a score of seven or more, we considered that the methodology of this publication was good.

Two authors extracted data and assessed the quality of eligible articles. The authors wrote to the corresponding authors for additional information if essential information was found to be incomplete.

Statistical analyses {#sec2-3}
--------------------

We used Review Manager to combine the results of individual studies. The *Z* test was employed to assess associations between polymorphisms in *CTLA-4/IL-18* and susceptibility to viral hepatitis in dominant, recessive, over-dominant and allele comparisons. All *CTLA-4/IL-18* polymorphisms contain a major allele (M) and a minor allele (m), the dominant comparison is defined as MM *vs.* Mm + mm, recessive comparison is defined as mm *vs.* MM + Mm, over-dominant comparison is defined as Mm *vs.* MM + mm and the allele comparison is defined as M *vs.* m. The statistical significant threshold of the *P* value was set at 0.05. *I*^2^ statistics were used to assess between-study heterogeneities. Random-effect models (DerSimonian--Laird method) were used to combine the results if *I*^2^ is larger than 50%. Otherwise, fixed-effect models (Mantel--Haenszel method) were used to combine the results. We also carried out subgroup analyses first by type of disease and then by ethnicity of participants. We examined the stability of combined results by deleting one study each time and combining the results of the remaining studies. Funnel plots were used to estimate whether our combined results may be influenced by overt publication biases.

Results {#sec3}
=======

Characteristics of included studies {#sec3-1}
-----------------------------------

We identified 271 articles during literature searching. Fifty-nine articles were assessed for eligibility after excluding unrelated or duplicate publications. We further excluded 16 reviews and four case controls, and another two articles were excluded because of missing crucial data. Totally 37 articles were ultimately included in this meta-analysis ([Fig. 1](#fig01){ref-type="fig"}). Extracted data of eligible articles are shown in [Table 1](#tab01){ref-type="table"}. Fig. 1.Flowchart of study selection for the present study. Table 1.The characteristics of included studies for this meta-analysisFirst author, yearCountryEthnicityType of diseaseSample sizeGenotype distribution*P*-Value for HWENOS scoreCasesControls*CTLA-4* rs231775Chen 2014ChinaEast AsianHBV465/204198/214/5382/102/200.1468Danilovic 2012BrazilMixedHCV112/18359/34/1981/67/350.0037Duan 2011ChinaEast AsianHBV172/14550/89/3361/68/160.6487Enciso-Vargas 2018MéxicoMixedHCV205/21567/104/3493/89/330.1347Gu 2010ChinaEast AsianHBV570/407244/251/75183/179/450.9028Jiang 2007ChinaEast AsianHBV24/1435/15/470/61/120.8007Khorshied 2014EgyptSouth AsianHCV52/46028/40/5203/204/530.8727Ksiaa 2015TunisiaSouth AsianHCV500/358225/198/77176/142/400.1687Mohammad 2006IranSouth AsianHBV51/1509/16/2641/52/57\<0.0018Sepahi 2017IranSouth AsianHCV65/65NANANA7Thio 2004USAMixedHBV378/676NANANA7Xiao 2015ChinaEast AsianHCV816/375358/375/83176/168/310.3008Zhang 2012ChinaEast AsianHBV172/14550/89/3361/68/160.6488*CTLA-4* rs5742909Chen 2014ChinaEast AsianHBV464/200342/112/10160/38/20.8778Danilovic 2012BrazilMixedHCV112/18392/19/1152/31/00.2117Duan 2011ChinaEast AsianHBV172/145141/28/3105/39/10.1947Enciso-Vargas 2018MéxicoMixedHCV205/215183/22/0193/21/10.6047Khorshied 2014EgyptSouth AsianHCV54/50333/13/8403/67/29\<0.0017Mohammad 2006IranSouth AsianHBV51/15041/10/0134/16/00.4928Schott 2007GermanyCaucasianHBV323/202276/42/5150/47/50.5707Sepahi 2017IranSouth AsianHCV65/6555/10/055/9/10.3927Thio 2004USAMixedHBV378/676NANANA7Xiao 2015ChinaEast AsianHCV816/375523/269/24266/99/100.8298Zhang 2012ChinaEast AsianHBV172/145141/28/3105/39/10.1948*CTLA-4* rs3087243Chen 2014ChinaEast AsianHBV467/203301/148/18116/79/80.2238Danilovic 2012BrazilMixedHCV112/18338/53/2162/95/260.2797Ksiaa 2015TunisiaSouth AsianHCV500/358194/217/89124/158/760.0567Thio 2004USAMixedHBV378/676NANANA7Xiao 2015ChinaEast AsianHCV816/375555/231/30266/99/100.8298*IL-18* rs1946518Abdelraheem 2016EgyptSouth AsianHCV100/10021/47/3242/51/70.1047An 2008USACaucasianHCV384/212NANANA7An 2008USAAfricanHCV364/182NANANA7Bakr 2018EgyptSouth AsianHCV189/9030/79/8024/48/180.4988Bao 2015ChinaEast AsianHBV153/16537/73/4341/76/480.3228Bouzgarrou 2008TunisiaSouth AsianHCV81/8224/38/1921/44/170.4938Cheong 2010South KoreaEast AsianHBV696/313183/321/19287/148/780.3447Dai 2017ChinaEast AsianHBV250/25061/134/5564/124/620.9008Estfanous 2019EgyptSouth AsianHCV201/9570/92/3947/37/110.3788Falleti 2007ItalyCaucasianHCV46/10512/22/1233/42/300.0418Haas 2009GermanyCaucasianHCV757/791276/347/134300/369/1220.6288Hirankarn 2007ThailandEast AsianHBV140/14033/68/3939/83/180.0128Imran 2014PakistanSouth AsianHCV140/12025/50/5535/53/320.2037Karra 2015IndiaSouth AsianHBV271/28070/152/49102/144/340.1208Ksiaa 2011TunisiaSouth AsianHCV100/10030/44/2626/50/240.9978Li 2012ChinaEast AsianHBV501/301121/239/14185/156/600.4487Lu 2015ChinaEast AsianHBV129/16032/58/3940/73/470.2788Mandour 2014EgyptSouth AsianHCV123/12320/63/4026/58/390.6088Migita 2009JapanEast AsianHBV204/6355/119/3020/30/130.7778Santos 2015BrazilMixedHCV304/37636/156/11268/192/1160.4598Wu 2011ChinaEast AsianHBV12/1093/8/137/46/260.1247Yue 2013ChinaEast AsianHCV552/784NANANA7Zhang 2005ChinaEast AsianHBV231/30053/116/6274/160/660.2438*IL-18* rs187238An 2008USACaucasianHCV384/212NANANA7An 2008USAAfricanHCV364/182NANANA7Bakr 2018EgyptSouth AsianHCV189/9099/87/330/58/2\<0.0018Bao 2015ChinaEast AsianHBV153/165122/28/3106/54/50.5488Bouzgarrou 2008TunisiaSouth AsianHCV81/8238/31/1235/35/120.5068Cheong 2010South KoreaEast AsianHBV707/316546/155/6237/67/120.0137Dai 2017ChinaEast AsianHBV250/250200/48/2183/65/20.1428Estfanous 2019EgyptSouth AsianHCV201/95102/94/552/36/70.8248Falleti 2007ItalyCaucasianHCV50/9623/23/449/38/90.6818Haas 2009GermanyCaucasianHCV757/791386/315/56439/299/530.8298Hirankarn 2007ThailandEast AsianHBV140/140105/29/6102/35/30.9998Imran 2014PakistanSouth AsianHCV140/12057/70/1343/61/160.4377Jiang 2014ChinaEast AsianHBV276/254221/51/4168/80/60.3247Karra 2015IndiaSouth AsianHBV271/280123/134/14159/108/130.3208Ksiaa 2011TunisiaSouth AsianHCV100/10053/33/1444/44/120.8458Lu 2015ChinaEast AsianHBV129/160100/27/2103/52/50.6108Migita 2009JapanEast AsianHBV204/63167/32/552/10/10.5318Santos 2015BrazilMixedHCV304/376100/120/84128/132/116\<0.0018Wu 2011ChinaEast AsianHBV12/10911/1/085/22/20.6827Yue 2013ChinaEast AsianHCV552/784NANANA7Zhang 2005ChinaEast AsianHBV231/300182/45/4202/90/80.5888[^2]

Meta-analysis results for polymorphisms in CTLA-4 and viral hepatitis {#sec3-2}
---------------------------------------------------------------------

Fourteen eligible articles were about *CTLA-4* polymorphisms and viral hepatitis. *CTLA-4* rs231775 (recessive comparison: OR 1.33, 95% CI 1.23--1.43) polymorphism was found to be significantly associated with viral hepatitis in overall combined analyses. Further subgroup analyses revealed similar positive findings for *CTLA-4* rs231775 polymorphism in HBV, especially among East Asians. A significant association with HCV was also detected for *CTLA-4* rs5742909 polymorphism (see [Table 2](#tab02){ref-type="table"}). Table 2.Meta-analysis results of this studyVariablesSample sizeDominant comparisonRecessive comparisonOver-dominant comparisonAllele comparison*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*CTLA-4* rs231775Overall3582/35260.050.83 (0.69--1.00)**0.0011.31 (1.11--1.55)**0.161.15 (0.95--1.40)0.140.88 (0.74--1.04)HBV1832/1870**0.030.70 (0.51--0.96)0.0021.46 (1.15--1.86)**0.681.03 (0.88--1.22)**0.00070.75 (0.63--0.88)**East Asian1403/10440.060.71 (0.51--1.12)**0.0061.43 (1.11--1.85)**0.601.05 (0.89--1.24)**0.020.76 (0.60--0.96)**HCV1750/16560.640.94 (0.73--1.21)0.141.19 (0.94--1.49)0.511.05 (0.90--1.23)0.070.90 (0.80--1.01)South Asian617/8830.850.95 (0.62--1.79)0.141.32 (0.91--1.91)0.341.97 (0.48--3.07)0.280.55 (0.19--1.61)*CTLA-4* rs5742909Overall2812/28590.800.96 (0.68--1.34)0.121.43 (0.91--2.25)1.001.00 (0.72--1.39)0.930.99 (0.75--1.30)HBV1560/15180.471.21 (0.72--2.04)0.421.39 (0.63--3.07)0.380.79 (0.47--1.34)0.251.21 (0.87--1.67)East Asian808/4900.491.26 (0.66--2.38)0.132.35 (0.77--7.12)0.370.74 (0.38--1.44)0.621.14 (0.67--1.95)HCV1252/1341**0.0030.73 (0.60--0.90)**0.181.46 (0.84--2.52)**0.011.32 (1.07--1.64)**0.080.75 (0.54--1.03)South Asian119/5680.240.58 (0.23--1.44)0.052.25 (0.99--5.09)0.081.66 (0.94--2.91)0.340.63 (0.24--1.64)*CTLA-4* rs3087243Overall2273/17950.351.08 (0.92--1.26)0.840.97 (0.75--1.27)0.420.94 (0.80--1.10)0.740.97 (0.78--1.19)HBV845/8790.071.36 (0.97--1.90)0.960.98 (0.42--2.29)0.070.73 (0.52--1.03)0.850.95 (0.58--1.57)HCV1428/9160.911.01 (0.84--1.21)0.840.97 (0.74--1.28)0.991.00 (0.84--1.20)0.940.99 (0.81--1.22)*IL-18* rs1946518Overall6270/5800**\<0.00010.82 (0.75--0.90)0.00081.29 (1.11--1.50)**0.490.97 (0.89--1.05)**\<0.00010.76 (0.68--0.86)**HBV2587/2081**0.010.84 (0.73--0.96)**0.101.20 (0.97--1.49)0.910.99 (0.88--1.12)**0.0090.82 (0.70--0.95)**East Asian2316/18010.110.89 (0.77--1.03)0.211.16 (0.92--1.47)0.590.97 (0.85--1.10)**0.030.83 (0.71--0.98)**HCV3683/3719**0.0040.73 (0.59--0.91)0.0031.38 (1.11--1.71)**0.390.95 (0.85--1.07)**0.00080.73 (0.60--0.88)**South Asian1486/1494**0.0010.65 (0.52--0.81)0.0081.65 (1.14--2.38)**0.180.87 (0.71--1.06)**0.0040.67 (0.51--0.88)***IL-18* rs187238Overall5495/4965**0.031.25 (1.03--1.52)**0.120.86 (0.71--1.04)0.080.85 (0.71--1.02)**0.0071.20 (1.05--1.37)**HBV2373/2037**0.031.39 (1.04--1.86)**0.110.72 (0.48--1.07)**0.040.73 (0.54--0.98)0.021.33 (1.05--1.70)**East Asian2102/1757**\<0.00011.53 (1.32--1.79)0.040.61 (0.39--0.98)\<0.00010.67 (0.58--0.79)\<0.00011.47 (1.28--1.68)**HCV3122/29280.491.08 (0.86--1.36)0.370.91 (0.73--1.12)0.971.00 (0.83--1.22)0.361.04 (0.95--1.14)South Asian510/392**0.0041.49 (1.13--1.95)**0.650.90 (0.57--1.42)**0.0090.70 (0.53--0.91)0.021.27 (1.04--1.55)**[^3][^4]

Meta-analysis results for polymorphisms in IL-18 and viral hepatitis {#sec3-3}
--------------------------------------------------------------------

Twenty-three articles were about *IL-18* polymorphisms and viral hepatitis. *IL-18* rs1946518 (dominant comparison: OR 0.82, 95% CI 0.75--0.90; recessive comparison: OR 1.29, 95% CI 1.11--1.50; allele comparison: OR 0.76, 95% CI 0.68--0.86) and *IL-18* rs187238 (dominant comparison: OR 1.25, 95% CI 1.03--1.52; allele comparison: OR 1.20, 95% CI 1.05--1.37) polymorphisms were both found to be significantly associated with viral hepatitis in overall combined analyses. Further subgroup analyses revealed similar positive findings for *IL-18* rs1946518 and rs187238 polymorphisms in HBV, especially among East Asians. Moreover, we also found that *IL-18* rs1946518 and rs187238 polymorphisms were significantly associated with susceptibility to HCV, especially among South Asians (see [Table 2](#tab02){ref-type="table"}).

Sensitivity analyses {#sec3-4}
--------------------

Stabilities of combined results were examined by deleting one study each time and combining the results of the remaining studies. The trends of associations remained consistent in sensitivity analyses, indicating that the combined results were statistically stable.

Publication biases {#sec3-5}
------------------

Funnels plots were employed to estimate whether our combined results may be influenced by overt publication biases. Funnel plots were overall symmetrical, indicating that the combined results were unlikely to be seriously impacted by overt publication biases (see Supplementary Fig. S1).

Discussion {#sec4}
==========

The combined results of this meta-analysis revealed that *CTLA-4* rs231775, *IL-18* rs1946518 and *IL-18* rs187238 polymorphisms were significantly associated with susceptibility to HBV, especially among East Asians. Moreover, *CTLA-4* rs5742909, *IL-18* rs1946518 and *IL-18* rs187238 polymorphisms were also found to be significantly associated with susceptibility to HCV, especially among South Asians. The trends of associations remained consistent in sensitivity analyses, indicating that the combined results were stable.

Some points need to be considered when interpreting our findings. First, past pre-clinical studies found that rs231775, rs5742909 and rs3087243 polymorphisms in *CTLA-4* as well as rs1946518 and rs187238 polymorphisms in *IL-18* could alter transcription activity or protein structure of *CTLA-4/IL-18* \[[@ref11]--[@ref14]\]. So these variations may influence biological function of *CTLA-4/IL-18*, result in immune dysfunction, impact anti-viral immune responses and ultimately confer susceptibility to viral hepatitis. Thus, our meta-analysis may be statistically insufficient to observe the real underlying associations between polymorphisms in *CTLA-4/IL-18* and viral hepatitis in certain groups. Therefore, future studies with larger sample sizes still need to confirm our findings. Second, according to our searching results, studies about HBV were mainly conducted in East Asians, whereas studies in HCV were mainly conducted in South Asians. So we call on scholars to examine associations between polymorphisms in *CTLA-4/IL-18* and viral hepatitis in other populations. Third, the etiologies of viral hepatitis are extremely complex, so we highly recommend further genetic association studies to explore the effects of haplotypes and gene--gene interactions on disease susceptibility \[[@ref15]\]. Fourth, we aimed to investigate associations between all polymorphisms in *CTLA-4/IL-18* and viral hepatitis in the very beginning. However, we did not find any study on other *CTLA-4/IL-18* polymorphisms. Nor did we find any studies about HAV, HDV or HEV. So we only focused on associations of five polymorphisms with HBV and HCV in this meta-analysis.

Like all meta-analyses, this study also has some limitations. Firstly, the results regarding associations between polymorphisms in *CTLA-4/IL-18* and viral hepatitis were based on combining unadjusted findings of eligible studies due to the lack of raw data \[[@ref16]\]. Secondly, the relationship between polymorphisms in *CTLA-4/IL-18* and viral hepatitis may also be affected by environmental factors. Nevertheless, the majority of eligible studies only focused on associations between polymorphisms in *CTLA-4/IL-18* and viral hepatitis, so we could not explore genetic-environmental interactions in this meta-analysis \[[@ref17]\]. Thirdly, grey literatures were not searched. Thus, despite that funnel plots were overall symmetrical, we still could not rule out the possibility that our combined results may be affected by potential publication biases \[[@ref18]\].

Conclusions {#sec5}
===========

In summary, this meta-analysis demonstrated that *CTLA-4* rs231775, *IL-18* rs1946518 and *IL-18* rs187238 polymorphisms may confer susceptibility to HBV in East Asians, while *CTLA-4* rs5742909, *IL-18* rs1946518 and *IL-18* rs187238 polymorphisms may confer susceptibility to HCV in South Asians. However, it should be noted that the combined results of this meta-analysis should still be confirmed by future studies with larger sample sizes.
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